SEARCH:   Advanced

Blood, 15 June 2004, Vol. 103, No. 12, pp. 4429-4431. Prepublished online as a Blood First Edition Paper on March 11, 2004; DOI 10.1182/blood-2003-11-3883. This Article Full Text (PDF) All Versions of this Article: 2003-11-3883v1 103/12/4429    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Gordon, L. I Articles by White, C. A Search for Related Content PubMed PubMed Citation Articles by Gordon, L. I Articles by White, C. A Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted November 12, 2003 Accepted February 4, 2004 Durable Responses After Ibritumomab Tiuxetan Radioimmunotherapy for CD20+ B-Cell Lymphoma: Long Term Follow-up of a Phase I/II Study Leo I Gordon*, Arturo Molina, Thomas Witzig, Christos Emmanouilides, Andrew Raubitschek, Mohamed Darif, Russell J Schilder, Greg Wiseman, and Christine A White Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA IDEC Pharmaceuticals, San Diego, CA, USA Mayo Clinic and Mayo Foundation, Rochester, NM, USA University of California, Los Angeles, CA, USA City of Hope Cancer Center, Duarte, CA, USA Fox Chase Cancer Center, Philadelphia, PA, USA * Corresponding author; email: l-gordon{at}northwestern.edu. We previously demonstrated that yttrium-90 (Y-90) ibritumomab tiuxetan (Zevalin®) radioimmunotherapy (RIT) was safe and effective for relapsed or refractory CD20+, B-cell, non-Hodgkin's lymphoma (NHL). We now provide long-term follow-up data in responding patients based on International Workshop Response Criteria. Complete (CR), CR unconfirmed (CRu) and partial response (PR) rates were 29%, 22%, and 22%, respectively (overall response rate 73%, 51% in CR/CRu). Mean TTP and DR in responders were 12.6 months and 11.7 months, respectively. At the maximum tolerated dose (0.4 mCi/kg), TTP and DR in complete responders (CR/CRu) were 28.3 and 27.5 months, respectively. Nine patients (24% of responding patients) had a TTP of greater than 3 years. Long-term responders (>5 years) have been identified. Zevalin® produces durable responses in patients with indolent and diffuse large B-cell lymphoma. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. M. Evens, W. G. Spies, I. B. Helenowski, D. Patton, S. Spies, B. D. Jovanovic, S. Miyata, E. Hamilton, D. Variakojis, J. Chen, et al. The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [90Y]Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin's Lymphoma: Preclinical Findings and Results of a Phase I Trial Clin. Cancer Res., October 15, 2009; 15(20): 6462 - 6471. [Abstract] [Full Text] [PDF] T. M. Illidge, M. Bayne, N. S. Brown, S. Chilton, M. S. Cragg, M. J. Glennie, Y. Du, V. Lewington, J. Smart, J. Thom, et al. Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy Blood, February 12, 2009; 113(7): 1412 - 1421. [Abstract] [Full Text] [PDF] L. Devizzi, A. Guidetti, C. Tarella, M. Magni, P. Matteucci, E. Seregni, C. Chiesa, E. Bombardieri, M. Di Nicola, C. Carlo-Stella, et al. High-Dose Yttrium-90-Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation J. Clin. Oncol., November 10, 2008; 26(32): 5175 - 5182. [Abstract] [Full Text] [PDF] B. D. Cheson and J. P. Leonard Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma N. Engl. J. Med., August 7, 2008; 359(6): 613 - 626. [Full Text] [PDF] R. M. Sharkey, H. Karacay, S. Litwin, E. A. Rossi, W. J. McBride, C.-H. Chang, and D. M. Goldenberg Improved Therapeutic Results by Pretargeted Radioimmunotherapy of Non-Hodgkin's Lymphoma with a New Recombinant, Trivalent, Anti-CD20, Bispecific Antibody Cancer Res., July 1, 2008; 68(13): 5282 - 5290. [Abstract] [Full Text] [PDF] P. L. Zinzani, M. Tani, S. Fanti, V. Stefoni, G. Musuraca, P. Castellucci, E. Marchi, M. Farsad, M. Fina, C. Pellegrini, et al. A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients Ann. Onc., April 1, 2008; 19(4): 769 - 773. [Abstract] [Full Text] [PDF] M. S. Czuczman, C. Emmanouilides, M. Darif, T. E. Witzig, L. I. Gordon, S. Revell, K. Vo, and A. Molina Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Patients Treated With Ibritumomab Tiuxetan Radioimmunotherapy J. Clin. Oncol., September 20, 2007; 25(27): 4285 - 4292. [Abstract] [Full Text] [PDF] F. Morschhauser, T. Illidge, D. Huglo, G. Martinelli, G. Paganelli, P. L. Zinzani, S. Rule, A. M. Liberati, N. Milpied, G. Hess, et al. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation Blood, July 1, 2007; 110(1): 54 - 58. [Abstract] [Full Text] [PDF] C. Soussain, L. L. Muldoon, C. Varallyay, K. Jahnke, L. DePaula, and E. A. Neuwelt Characterization and Magnetic Resonance Imaging of a Rat Model of Human B-Cell Central Nervous System Lymphoma Clin. Cancer Res., April 15, 2007; 13(8): 2504 - 2511. [Abstract] [Full Text] [PDF] T. M. Habermann Antibody Therapy in Aggressive Lymphomas Hematology, January 1, 2007; 2007(1): 257 - 264. [Abstract] [Full Text] [PDF] R. M. Sharkey and D. M. Goldenberg Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates CA Cancer J Clin, July 1, 2006; 56(4): 226 - 243. [Abstract] [Full Text] [PDF] P. S. Conti, C. White, P. Pieslor, A. Molina, J. Aussie, and P. Foster The Role of Imaging with 111In-Ibritumomab Tiuxetan in the Ibritumomab Tiuxetan (Zevalin) Regimen: Results from a Zevalin Imaging Registry J. Nucl. Med., November 1, 2005; 46(11): 1812 - 1818. [Abstract] [Full Text] [PDF] A. Nademanee, S. Forman, A. Molina, H. Fung, D. Smith, A. Dagis, C. Kwok, D. Yamauchi, A.-L. Anderson, P. Falk, et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma Blood, October 15, 2005; 106(8): 2896 - 2902. [Abstract] [Full Text] [PDF] J. P. Leonard Targeting CD20 in Follicular NHL: Novel Anti-CD20 Therapies, Antibody Engineering, and the Use of Radioimmunoconjugates Hematology, January 1, 2005; 2005(1): 335 - 339. [Abstract] [Full Text] [PDF] R. M. Sharkey and D. M. Goldenberg Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies J. Nucl. Med., January 1, 2005; 46(1_suppl): 115S - 127S. [Abstract] [Full Text] [PDF] M. S. Czuczman, R. Weaver, B. Alkuzweny, J. Berlfein, and A. J. Grillo-Lopez Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-Up J. Clin. Oncol., December 1, 2004; 22(23): 4711 - 4716. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020